All In Biotech

Drug Trial Radar · NCT06600412

The Evaluation of the Drug R3R01 for the Excretion of Protein in the Urine in Patients With Diabetic Kidney Disease.

Effects of the ABCA1 Inducer R3R01 on Albuminuria Levels in Diabetic Kidney Disease

Last checked: Nov 19, 2026Latest source record: Sep 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Oct 10, 2024

Primary completion

Apr 1, 2027

Study completion Apr 1, 2027

Sponsor

Lead sponsor
River 3 Renal Corp.Industry
Sponsor type
Industry
Collaborators
Region Hovedstadens Apotek; Copenhagen University Hospital at Herlev; Q2 Solutions; LUMIS International GmbH
First posted
Sep 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to to investigate whether the drug R3R01 has a beneficial effect on the amount of protein excreted in the urine in adult patients (above 18 years of age) with type 2 diabetes and resulting kidney disease. The main questions it aims to answer are: 1. Does 3 months of treatment with 200mg of the drug R3R01 morning and evening have a beneficial effect on the amount of protein excreted in the urine in patients with type 2 diabetes and kidney disease? 2. Does R3R01 have an effect on kidney function and daily blood pressure? Researchers will compare the results of 40 people who take R3R01 to 20 people who receive an inactive substance (placebo). Participants will receive R3R01 or the placebo as an oral tablet and undergo a selection of medical examinations - such as: * blood samples * urine tests * kidney tests involving a radiolabelled marker which is injected into the bloodstream and monitored via blood samples * 24 hour blood pressure monitoring via a wearable device * urine pregnancy test (if applicable)

Conditions

  • Diabetic Kidney Disease

Interventions

  • R3R01Drug

    R3R01 is an ATP-binding cassette transporter A1 (ABCA1) inducer, which increases the efflux of cholesterol from the intracellular space in the kidney. Please refer to arm/group description for further information.

  • PlaceboDrug

    Please refer to arm/group description for further information.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Urinary albumin-to-creatinine ratio (UACR)Time frame: 12 weeks (84 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Steno Diabetes Center Copenhagen

    Copenhagen, Copenhagen, Denmark · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.